Jason Ehrlich - 24 Jun 2023 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Reporting relationship: Chief Medical Officer and Chief Development Officer
Issuer ticker: KOD
Reported as of: 24 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2023, 17:35:28 UTC
Prior SEC filing: 16 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich

Key filing fact

Jason Ehrlich filed Form 4 for Kodiak Sciences Inc. (KOD) on 27 Jun 2023.

Key facts

This page summarizes Jason Ehrlich's Form 4 filing for Kodiak Sciences Inc. (KOD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2023, 17:35.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KOD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +207,500
Change %
Price: $0.000000
Shares after: 207,500
Date: 24 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 207,500
Exercise price: $7.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-forty-eighth (1/48th) of the shares vest one month after July 1, 2023 (the "Vesting Commencement Date"); the balance of the shares vest in a series of forty-seven (47) successive equal monthly installments measured from the first month anniversary of the Vesting Commencement Date, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC remarks

Chief Medical Officer and Chief Development Officer